Author: Nichols Martin|| Date Published: March 31, 2021
The U.S. Army has reserved at least 100,000 doses of AstraZeneca’s AZD7442, a long-acting antibody product designed to prevent COVID-19 infection or treat the coronavirus disease, through a $204.9 million contract modification.
The service branch obligated the full amount using its fiscal 2021 research, development, test and evaluation funds, the Department of Defense said Tuesday.
Contract work will take place in Wilmington, Delaware, through Dec. 31.
AstraZeneca licensed the AZD7442 combination therapy of two long-acting antibodies from the Vanderbilt University Medical Center in Nashville, Tennessee, last year and engineered the drug using the company’s proprietary half-life extension technology.
A Phase III clinical trial is underway to evaluate the efficacy and safety of the LAAB combo product as a treatment for non-hospitalized COVID-19 patients.
Pradeep Paruchuri, senior director of solutions engineering at UiPath, said agentic artificial intelligence could help government agencies improve efficiency by…
Redhawk Federal Solutions has acquired Twenty8 Technology to expand its data interoperability and artificial intelligence and machine learning engineering capabilities.…
